FEATURED COMPANY

VORTEX RESOURCES CORPORATION (OTCBB: VXRC)

Detailed Quote: http://www.otcpicks.com/quotes/VXRC.php

Company Profile: http://www.otcpicks.com/vortex-resources-corp.htm

The Company's business has been the identification and acquisition of undervalued assets within emerging industries for the purpose of consolidation and development of these businesses and sale if favorable market conditions exist. The Company's objective is to find, acquire and develop resources at the lowest cost possible and recycle its cash flows into new projects yielding the highest returns with controlled risk. The Company's competencies include financial services, mergers and acquisitions, accounting, real estate development, and natural resources exploration. The Company is currently in the process of developing a logistics center. As part of its strategy to develop a logistics center, the Company has entered a term sheet with Yasheng Group in which Yasheng Group, among other things, has agreed to contribute real property for the development of a logistics center. Further, the Company and Yasheng Group have jointly entered into a cooperation agreement with Legend Transportation based in Texas. As a result of the above, the Company is in the process of changing its name to Yasheng Eco-Trade Corporation.

VXRC News:

June 24 - Vortex Resources Signs Agreement to Establish Yasheng Group Russia

Enters MOU with Create Agrogroup for Stock Breeding Complex in Russia

Vortex Resources Corp. (OTCBB: VXRC) (Equity, ISIN US92905M2035, WKN A0RLEK, HTE2), which is in the process of changing its name to Yasheng Eco-Trade Corporation, has signed an Agreement creating the Yasheng Group Russia. The Yasheng Group Russia, as part of a Joint Venture with Create Agrogroup Zao (“Create”), will be developing an Eco-Trade distribution and logistics center in Russia similar to the one the company is currently working on in Southern California.

The joint venture is the culmination of several months of negotiations headed by former Prime Minister of Tajikistan and ambassador to Russia Abdoumalik Abdoulladjanov. The first stage of the development is a Stock Breeding Complex in the Russian Federation. The purpose of the development will be to increase exports to China, which management believes will be a significant opportunity for the company. Create has been working for several years acquiring over 220 acres of land and has recently received approval to begin stage one of the developments.

The development is expected to be built out in three stages over five years at an estimated cost of $186 million.

The development of the joint venture in Russia is contingent upon the completion of due diligence by all parties, executing definitive agreements and raising the needed capital. As such, there is no guarantee that we will be successful in development of this joint venture.

ABOUT CREATE AGROGROUP

Create Agrogroup ZAO was established in January 2006 in Balakovo of Saratov region for the operational management of “Saratov Agricultural Group” Project implementation. Managers of company have extensive experience of agricultural project implementation.

FEATURED COMPANY

PRECISION PETROLEUM CORPORATION (OTCBB: PPTO)

Detailed Quote: http://www.otcpicks.com/quotes/PPTO.php

Company Profile: http://www.otcpicks.com/precision-petroleum.htm

Precision Petroleum Corporation is an independent energy company engaged in the acquisition, exploration and development of oil and natural gas properties in the United States. Precision's objective is to seek out and develop opportunities in the oil and natural gas sectors that represent a low risk opportunity. As well, Precision aims to define larger projects that can be developed with Joint Venture partners.

PPTO News:

June 25 - Precision Petroleum Corporation-Acquires Working Interest in the Ward/McNeil #1 Well, Garvin County, Oklahoma

Precision Petroleum Corp. (OTCBB: PPTO) (the "Company") has recently completed the purchase of a working interest in an oil and gas lease in Garvin County, Oklahoma.

Ward/McNeil #1 represents the 13th working interest purchased by the Company over the past 2 months.

This well was initially completed in the Basal Pennsylvanian Sandstone/Viola Limestone reservoirs after a minor frac entry into these formations.

The well was producing approximately 12 barrels of oil and 100 MCF of natural gas per day after the initial treatment. The Company intends to re-enter these formations with a major frac which should substantially increase the production capacity of the reservoirs.

Richard Porterfield, Petroleum Geologist and President, is pleased with this acquisition. Although the well is presently considered a minor producer, we anticipate that we will be able to quickly recover our investment and extended profits after the re-completion is finalized.

Mr. Porterfield also stated that he and other oil and gas consultants are presently assessing the acquisition of a 6 well producing package. This operation also has an abundance of spacing for a further 6 well expansion development, with multiple reservoirs. In view of current commodity prices, this addition would be a major boost to the Company's cash flow and bottom line profits. Negotiations have commenced during which various technical analysis examinations and reservoir evaluation programs by the Company are underway.

FEATURED COMPANY

QUOTEMEDIA INCORPORATED (OTCBB: QMCI)

Detailed Quote: http://www.otcpicks.com/quotes/QMCI.php

Company Profile: http://www.otcpicks.com/quotemedia/quotemedia.htm

QuoteMedia, Inc. is a leading software developer and provider of real-time streaming financial market information, decision-support, news and research solutions to brokerage, financial services companies, business and media corporations. Among its many leading-edge products lines, the Company offers data feeds, news, dynamic market content solutions, interactive stock research tools, financial applications and real-time wireless applications. QuoteMedia provides data and services for companies such as the NASDAQ, the OTCBB, Dow Jones & Company, Forbes.com, Scotia Capital, Business Wire, Southwest Securities, Regal Securities, FBR Direct, Broadridge Financial Solutions, Inc., AIM Trimark, Zacks Investment Research, ChoiceTrade, QTrade, Schaeffer's Investment Research, Automated Financial Systems, WallStreet*E, and others. For more information, visit www.quotemedia.com.

QMCI News:

June 3 - QuoteMedia Announces Enterprise Agreement with TradePMR

QuoteMedia, Inc. (OTCBB: QMCI), a leading provider of market data, corporate research information and financial applications, announced an enterprise agreement with TradePMR, Inc. TradePMR is a major provider of brokerage and custody services, and related technology, to the financial services industry.

TradePMR will integrate a wide array of QuoteMedia’s offerings into its eCustody platform, which it currently provides to 420 independent RIA firms for use by their investment advisors.

Contracted QuoteMedia services include raw quote and research data via QuoteMedia’s DataFeed solutions, and an extensive array of QuoteMedia’s content and research products. In addition, TradePMR will provide its clients with QuotestreamTM Professional and Quotestream Wireless, QuoteMedia’s streaming real-time portfolio management system for brokers and financial advisors.

"In order to maintain and improve our competitive position, it is vital that we continue to provide our clients with unmatched market and research information, timely data, technological excellence and the highest level of customer service. By incorporating QuoteMedia's market solutions into our new and existing offerings, we are able to go the extra step in creating an outstanding offering for our clients," says Robb W. Baldwin, President and CEO of TradePMR. "With QuoteMedia's superior technologies and breadth of market coverage, we are able to expand the depth of our financial data content to provide the timely, in-depth market information our clients require."

"We're very pleased to be partnering with TradePMR," says Dave Shworan, CEO of QuoteMedia Ltd. "TradePMR has a well deserved reputation for providing brokerage firms and financial advisers with the information, technology and support they need to manage clients' investments effectively and grow their business efficiently. Certainly this agreement represents a major growth opportunity for QuoteMedia, particularly with respect to increasing market acceptance for Quotestream Professional. To have a company like TradePMR choose to incorporate our solutions in such a wide-ranging manner represents a major endorsement of the quality of our offerings, and this is especially gratifying."

ABOUT TRADEPMR

TradePMR is a privately held brokerage firm (Member FINRA/SIPC) located in Gainesville, Florida. Since 1999, it has been a leading provider of Brokerage and Custody services to Independent Registered Investment Advisors (RIAs) and their clients by providing an integrated web-based workstation that enables RIAs to run their practices more efficiently and effectively.

FEATURED COMPANY

BABY BEE BRIGHT CORPORATION (OTC: BBYB)

Detailed Quote: http://www.otcpicks.com/quotes/BBYB.php

Company Profile: http://www.otcpicks.com/baby-bee-bright/baby-bee-bright.htm

Baby Bee Bright Corporation manages the Baby Bee BrightTM brand. Its executive staff, composed of professionals with over 30 years of experience in engineering research and marketing, have developed an innovative prenatal communication system, servicing the rapidly expanding expectant mother/prenatal market. The company has a patented, audio directional technology for its communicator which is designed for expectant mothers to safely and efficiently transmit music and sound to their babies. It allows mothers and family to bond with their babies before birth. Lullabies and classical music provide the baby with soothing sounds before and after birth.

BBYB News:

June 18 - Baby Bee Bright Corporation To Create New Product Video

Baby Bee Bright Corporation (OTC: BBYB), developer of a unique prenatal communication system is in the planning stage to develop a professionally shot video to help inform the public about the features and benefits of the Baby Bee Bright System and to also help educate expectant mothers on how to most effectively use the system. The company’s video will show the public and the expecting mothers the proper ways to use the communicator and the correct positioning of the speakers so that a mother’s unborn child can receive the best benefits from the system.

Fred Dahlman, CEO, states: “We think a professionally developed video will help to visually demonstrate the simplicity and effectiveness of using the Baby Bee Bright prenatal communication system. This new video can also help to explain the system’s features and benefits to potential users and should spur consumer interest in the product, interest and inquiries from prospective retailers, and ultimately new sales and product revenue. We intend to post our video on the company’s web site and we will also post it on YouTube.com which has enormous traffic and should help create interest and drive new sales. We think this video will ultimately be a boon for the company’s bottom line and we look forward to a positive public response to the video and ultimately increased sales.”

FEATURED COMPANY

KRAIG BIOCRAFT LABORATORIES INCORPORATED (OTCBB: KBLB)

Detailed Quote: http://www.otcpicks.com/quotes/KBLB.php

Company Profile: http://www.otcpicks.com/kraig-biocraft-laboratories/kraig-biocraft-laboratories.htm

Kraig Biocraft Laboratories, Inc. focuses on the development of protein based fiber using recombinant DNA technology for commercial applications in the textile and specialty fiber industries. Its products are used in military and police departments; industrial applications, including critical cables and abrasion/impact resistant components; and consumer applications. These fibers are also employed in safety equipment, and high strength composite materials for the aero-space industry. The company was founded in 2006 and is based in Lansing, Michigan.

KBLB News:

June 25 - SectorWatch.biz: The Super-Fiber Revolution

SectorWatch.biz announces the availability of an important new commentary of interest to investors in Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) and other high-performance fiber equities making news and driving markets today.

For decades scientists have been fascinated by the silk fibers that make up certain spider webs. In fact, spider silk is one of the strongest and most resilient fibers known to man, making it a potential "super fiber" for a host of ballistic resistant, medical, and industrial applications. We are told that spider silk is about five times stronger than steel and twice as strong as DuPont's market-leading Kevlar(r) on a pound-for-pound basis. Spider silk can also stretch about 30% longer than its original length without breaking, making its threads extremely resilient.

Kraig Biocraft Laboratories is developing a way of inserting spider silk DNA directly into silkworms allowing silkworms to produce the proteins for spider silk. Kraig is working in cooperation with University of Notre Dame scientists and laboratories to create new polymers with potentially broad applications for consumers and industry in the $92 billion marketplace for high performance fibers.

ABOUT SECTORWATCH.BIZ

SectorWatch.biz is powered by Market Pathways, a leader in the representation of smallcap equities for nearly thirty years.

STOCKS TO WATCH

HALIFAX CORPORATION OF VIRGINIA (AMEX: HX)
"Up 122.22% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/HX.php

Founded in 1967, Halifax Corporation of Virginia is an enterprise logistics and maintenance solutions company providing a wide range of technology services to commercial and government customers throughout the United States. The Company's principal products are enterprise logistics solutions and high availability hardware maintenance services.

HX News:

June 30 - Halifax Announces Fiscal 2009 Financial Results

Net Income of $903,000 and Earnings Per Share of $0.28

Halifax Corporation of Virginia (NYSE Amex: HX) announced its financial results for the quarter and fiscal year ended March 31, 2009.

Revenues for of fiscal year 2009 were $34.0 million compared to $43.9 million for the prior year. The decrease in revenues in 2009 was attributable to the termination of certain large nation-wide enterprise maintenance contracts, including the loss of a large aeronautic manufacturing customer at the end of fiscal year 2008.

The Company reported operating income of $1.3 million compare to an operating loss of $1.8 million for the prior fiscal year. The improvement in operating results was primarily due to the lowering of our operating costs which offset our reductions in revenue, and improvement in the mix of our business to more profitable contracts.

The Company reported net income of $903,000, or $.28 per basic and diluted share.

Charles McNew, President and Chief Executive Officer, stated, "It's a pleasure to be discussing profitable results on a full year basis. We are successfully executing a difficult transformation in an extremely challenging economic environment."

"Financial performance has improved on virtually every front, under performing contracts have been eliminated, margins are improving, working capital is growing and bank debt continues to decline."

For the quarter ended March 31, 2009 revenues were $8.0 million compared to $9.0 million for the same period last year. The Company had operating income of $268,000 compared to an operating loss of $887,000 for the same period last year. The Company reported net income of $241,000, or $.08, per basic and diluted share for the three months ended March 31, 2009, compared to a net loss of $955,000 or $(.30) per basic and diluted share for the quarter ended March 31, 2008.

McNew added, "We have every reason to believe that our return to profitability is sustainable going forward and as noted in a recent announcement, our supply chain services program (Enterprise Logistics Solutions) is being well received by the business process outsourcing community on both a domestic and international basis and is affording us a variety of higher margin growth opportunities. Our legacy maintenance business has its challenges but given the current state of our sales pipeline it appears to be on track for an acceptable performance in the coming year."

INTERNATIONAL AEROSPACE ENTERPRISES (OTCBB: IARO)
"Up 316.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/IARO.php

International Aerospace Enterprises, Inc. is an innovative and aggressive provider of discounted military aircraft spare parts for U.S. Ally partners throughout the world. The company offers inexpensive and shipment ready aircraft spare parts for both military and commercial aircraft users that meet all industry standards for quality manufacturing.

IARO News:

June 30 - International Aerospace Notified of $750,000.00 USD Bid Award

International Aerospace Enterprises, Inc. (OTCBB: IARO) announced that the company has been awarded a $750,000.00 USD bid award for military aircraft spare parts by the Egyptian Air Force. The award is immediate evidence that the company’s International Targeted Sales Strategy is right on target as reported in the June 18, 2009 news release titled “International Aerospace Enterprises Inc. Launches Targeted Worldwide Sales Program.” Mr. John Peck, IARO’s CEO, reported, “The initial sales to the Egyptian Air Force is the first of over $13 million USD in our international sales pipeline.”

He voiced some concern that, “IARO’s management team feels that the current and future value of the company is not reflected in the company’s current share price but is reflective of the decisions made by the shell’s previous management.” He continued by stating that he is, “confident that the Company’s international sales performance and future earnings will better reflect the real value of International Aerospace Enterprises, Inc. for both our company and our shareholders.”

Mr. Peck further stated, “I have some additional exciting news to report to our Shareholders. As of July 1, 2009, Mr. Saffet Uslu, our current exclusive International Sales representative, has accepted the position of President of IARO.”

Mr. Uslu has a Bachelor of Science and his Master’s degree in Mechanical Engineering from University of Southern California. He has obtained his dual citizenship in both the United States of America and the Republic of Turkey. His 14 years of experience in international military aircraft spare parts sales and his dual citizenship, with one of the United State’s key Allies in the Middle East, makes him an exceptional addition to IARO’s Management Team.”

Mr. Uslu stated, “I am both excited and proud to have been asked to join IARO’s Management team. To have an opportunity to be involved with an exciting company like IARO, at its foundational level, happens only once in a life time. I am dedicated and confident that IARO will produce exceptional shareholder value for in its stockholders in both the short-term and long-term through performance. I am prepared to work hard with our management team and for our shareholders.”

ARTFEST INTERNATIONAL INCORPORATED (OTCBB: ARTI)
"Up 37.93% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ARTI.php

Artfest International, Inc. is a publicly traded company that brings together artists, investors, decorators, designers, private collectors and art galleries. Artfest International's corporate site is www.artfestinternational.com. Artfest's subsidiaries are Art Channel, Inc. (www.artchannel.tv) and Art Channel Galleries, Inc. (www.ArtChannelGalleries.com), offering the most exciting product and rewards program in the history of direct sales marketing.

ARTI News:

June 24 - Artfest International, Inc. Establishing Worldwide 'Gold Standard' for Art and Collectibles Industry Through RFID Technology as Stated During Nationwide Teleconference

Company Looking to Complete Charity Sports Distribution Agreement Within the Next Week

Artfest International, Inc. (OTCBB: ARTI) announced that the Company is in the process of establishing the worldwide "gold" standard for how art and collectibles are marketed, tracked, and valued through its RFID technology. During the Company's nationwide teleconference yesterday, Edward Vakser, CEO of Artfest International, was able to update the financial community about Artfest International's RFID software functionality and applications within the art and collectibles sector, the $5 Million Equity Line of Credit that the Company recently finalized with Delaney Capital, as well as the status of its acquisition of Charity Sports Distribution, Inc. and what impact the acquisition will have on the Company. Ms. Angie Tassan, Chief Marketing Officer of Artfest International, Inc. discussed the Company's new Expo Center that recently opened in Dallas, Texas, the artists that are under the Artfest "umbrella," and how through www.artchannelgalleries.com, anyone can own their own fine art gallery.

Mr. Vakser explained how Artfest's business model based around its RFID technology and software package keeps all players in the art and collectibles industry "honest." During the call, Mr. Vakser gave the example that if a consumer bought a limited edition collectible embedded with Artfest's RFID technology, then the consumer would be able to connect to a data base that shows them all the parameters of that particular collectible, where it was purchased, when it was purchased, for what amount it was purchased, what number of the limited edition they purchased, etc. Artists or athletes are able to see how many pieces or items were produced and/or sold. The information on the RFID chip can be read either through an iPhone, PDA, and/or with Artfest's reader package. "Artfest is also addressing the issue of forgeries and fraud in the art and collectible sector by offering an insurance based policy with every piece bought or sold through Artfest. If the owner of the piece maintains the policy, this will help maintain the true value as well as the overall 'provenance' of the piece. There is no other entity in our industry trying to achieve the standard we have established," stated Mr. Vakser.

Mr. Vakser also mentioned during the nationwide teleconference that Arftest International has completed a $5 Million Dollar equity line of credit with Delaney Capital, LLC. The Company plans to utilize the funds to complete various mergers and acquisitions. He stated that Artfest is looking to acquire collectible and framing companies, as well as securing the rights to artists and purchasing art galleries. Mr. Vakser expects that the acquisition of Charity Sports Distribution will be completed within a week now that the equity line of credit has been finalized. Mr. Vakser stated that the acquisition of Charity Sports Distribution would significantly increase the Company's revenues through Charity Sports Distribution's agreements with the Dallas Cowboys, Texas Rangers, the Dallas Stars, the Dallas Mavericks, as well as 27 College Teams.

Angie Tassan, the Chief Marketing Officer of Artfest International, explained that once the acquisition of Charity Sports Distribution is completed then Artfest would also be the official high end sports memorabilia dealer of the Dallas Cowboys. She also discussed the grand opening of the Company's 52,000 square foot Expo Center in Dallas. "We have hosted several events in the month of June at the Expo Center including the launch today of the Global Peace Project. This is a project that is in conjunction with one of our artists, D. Arthur Wilson and his character Rhupert," stated Ms. Tassan. She also explained that Artfest International currently has several artists under its "umbrella" including the Russian artist Kazanin, Randy Jacobs, and Lisa Wilson.

Ms. Tassan also discussed how anyone around the world could own their own fine art gallery online through www.artchannelgalleries.com. She explained how each member could customize their own online gallery, and that Artfest had the most advantageous rewards program. "Through technology, Artfest is able to promote and market art to the masses, track art, as well as insure art," stated Angie Tassan.

"We are looking to grow our revenue significantly in the near future through avenues such as expanding our wholly owned subsidiary, Art Channel Television, and opening new Expo Centers around the country," stated Mr. Vakser.

SYMPOWERCO CORPORATION (OTC: SYMW)
"Up 33.33% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/SYMW.php

SymPowerco Corporation develops advanced fuel cell and power delivery systems for the rapidly growing personal transportation and portable power system markets being created by today's energy and environmental challenges.

SYMW News:

June 30 - SymPowerco Signs LOI to Acquire Majority Stake in Highline Hydrogen Hybrids

SymPowerco Corporation (OTC: SYMW) CEO John Davenport announced that the company has signed a Letter of Intent ("LOI") with Texas businessman Steven Humphries for the acquisition of a majority interest in Highline Hydrogen Hybrids, Inc. ("HHHI"), the manufacturer of a unique and proven hydrogen conversion system for gasoline and diesel-powered vehicles.

In April of 2009, Humphries entered an agreement to purchase 70% of HHHI. Under the terms anticipated by today's Letter of Intent, Mr. Humphries will assign his HHHI interest to SymPowerco.

HHHI's unique supplemental hydrogen fuel system, in addition to reducing dangerous emissions, has been shown to enhance the fuel efficiency of internal combustion engines by as much as 25% and to increase horsepower by an average of 10%. HHHI also plans to release a commercial version of its supplemental fuel system for use on Over-The-Road commercial vehicles.

HHHI's unique hydrogen converter has undergone rigorous testing and has a patent pending. The company is currently relocating from Northwest Arkansas to a 380,000 square foot building on 30 acres in Dumas, Arkansas. HHHI officials project gross sales of their products to reach nearly $3,400,000.00 over the next 18 months.

Stated SymPowerco CEO John N. Davenport, "We at SymPowerco are very excited about the potential HHHI revenue streams and the synergies that HHHI's efficiency enhancing products could bring to our company. We believe that HHHI's products would complement our Flowing Electrolyte Direct Methanol Fuel Cell technologies by allowing SymPowerco to not only replace the internal combustion engine with the fuel cell in many applications but to also offer products to help reduce the environmental and energy-related impacts of the remaining fleet of vehicles powered by internal combustion engines."

SymPowerco Corporation develops advanced fuel cell and power delivery systems for the rapidly growing personal transportation and portable power system markets being created by today's energy and environmental challenges.

BIOVEST INTERNATIONAL INCORPORATED (OTCBB: BVTI)
"Up 8.16% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BVTI.php

Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ: ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently completing a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.

BVTI News:

June 28 - Personalized Anti-Cancer Vaccine, BiovaxID®, Targeting B-cell Lymphomas Available in Europe on a Named-Patient Basis

* Biovest and idis Partner to Facilitate Patient Access to Lymphoma Vaccine
* Phase III Study Results to Be Presented at “Best of ASCO” in Paris

Biovest International, Inc. (OTC: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTC: ABPIQ) announced that BiovaxID®, Biovest’s personalized therapeutic anti-cancer vaccine, is available on a named-patient (compassionate-use) basis in Europe. Following compliance with local regulatory protocols, BiovaxID will be supplied by idis Limited to European healthcare professionals for the treatment of follicular non-Hodgkin’s lymphoma and potentially for other B-cell blood cancers such as chronic lymphocytic leukemia, mantle cell lymphoma and multiple myeloma. Physicians in non-European countries may also contact idis to inquire about the potential availability of BiovaxID, as idis manages named-patient programs in more than 100 countries.

According to world-renowned hematologist and lymphoma research pioneer, Professor Volker Diehl, M.D., Ph.D., Professor of Medicine, University of Cologne, “With the availability of this truly patient-specific vaccine, I believe hematologists now have a new, safe lymphoma treatment option capable of enhancing existing chemotherapeutic and monoclonal antibody treatment options by training the patient’s own immune system to selectively recognize and attack cancer cells, resulting in potentially longer lasting remissions. As follicular lymphoma so far is supposed to be a generally incurable and fatal blood cancer, it is with great hope and expectations that I welcome such a highly personalized therapeutic approach in addressing an urgent unmet need.” Prof. Dr. Diehl founded the German Hodgkin Study Group and is a recipient of the Bundesverdienstkreuz (Order of Merit of the Federal Republic of Germany), awarded by the German government for his lifetime achievements in the field of lymphoma research.

The BiovaxID Phase III study results were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session, reporting that an eight year pivotal, randomized, multi-center, double-blind, controlled clinical study demonstrated that BiovaxID significantly prolonged disease-free survival in follicular non-Hodgkin’s lymphoma. The study found that patients who received BiovaxID experienced a median disease-free survival of 44.2 months compared to 30.6 months for those who received a control vaccine – an increase of 47 percent. In the study, with a median follow-up of 4.7 years, patients receiving BiovaxID experienced a 38% lower risk of disease recurrence compared to patients receiving the control vaccine. BiovaxID is the first vaccine targeting lymphoma ever to demonstrate such a disease-free survival benefit and because the vaccine is comprised of the patient’s own cells (autologous), the therapy has been demonstrated to be safe and well-tolerated.

Later today, the BiovaxID Phase III study results will again be presented at the “Best of ASCO” event to be held at the Maison de la Chimie, in Paris, France at 4:15 p.m. local time. The discussants for the BiovaxID abstract (abstract 33572) will be Jean-Luc Harousseau, M.D., Head of the Department of Clinical Hematology at the Central Laboratory of Hematology in Nantes, France and Vice President of the French Society of Hematology, and Christian Gisselbrecht, M.D., Ph.D., of the Institut d'Hématologie, Hôpital Saint-Louis in Paris, France.

Prof. Dr. Diehl also anticipates that the addition of BiovaxID booster shots could substantially bolster patient results, stating, “The recently reported Phase III results, while impressive, did not include a BiovaxID maintenance regimen consisting of periodic booster shots. Such a maintenance booster regimen may be key in continuing to stimulate a robust and enduring immune response, thus further improving results, and perhaps even resulting in durable remissions for some patients.” Biovest intends to include multiple booster vaccines for potential maintenance therapy purposes as part of the vaccine delivery for prescriptions processed under the named-patient program.

As BiovaxID is individually manufactured from a tissue biopsy obtained from a patient’s own tumor, a patient wishing to participate in the named-patient program must undergo a lymph node biopsy prior to receiving chemotherapy/monoclonal antibody therapy. Those cells collected by biopsy will then undergo a preparation process performed by Biovest with the resulting vaccine material then preserved until manufacture of the final vaccine is prescribed by the patient’s physician through idis. The vaccine is typically administered approximately 6 months following the end of chemotherapy, and consists of five BiovaxID vaccinations, subcutaneously injected, over a 6 month period (months 1,2,3,4 and 6). As an adjuvant therapy, at each vaccination cycle, patients will also receive four daily injections of an immune stimulating agent, GM-CSF. At the physician’s option, a periodic vaccine booster maintenance regimen may also be prescribed.

A named-patient program is a compassionate-use drug supply program under which physicians are permitted to supply investigational drugs to qualifying patients. Under a named-patient program, investigational drugs may be administered to patients who are suffering from a serious illness prior to the drug being approved by the European Medicines Evaluation Agency (EMEA). “Named-patient” distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient, assuming compliance with the local regulatory protocols respective to each participating country. In Europe, under the named-patient program, the drug is most often purchased through the national health system.

ABOUT BIOVAXID®

BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, it is anticipated that BiovaxID could be used to treat other types of B-cell cancers, such as mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma.

A Unique Approach to Immunotherapy Targeting B-Cell Blood Cancers

B-cells (a type of white blood cell or lymphocyte) are a vital part of the human immune system, as they produce antibodies that seek out and bind to foreign substances in the body. In lymphoma, as cancerous B-cells develop and multiply unrestrained, each malignant B-cell expresses a unique idiotype or biomarker on the cell’s surface, specific to each patient. Research at Stanford University and the National Cancer Institute led to the development of BiovaxID as a personalized, therapeutic vaccine capable of selectively targeting only cancerous B-cells, while sparing healthy cells. This is achieved by using the idiotype obtained from a sample of the patient’s tumor by biopsy, and through proprietary bioengineering techniques in a patented cell line, a patient-specific vaccine is created that stimulates the immune system by recruiting a patient’s T-cells (immune cells that kill cancerous cells) to seek out and destroy only the diseased B-cells. BiovaxID is the only hybridoma (patient’s lymphoma cells are fused to a heteromyeloma cell line to produce the tumor specific idiotype protein) anti-cancer vaccine that consists of a high-fidelity copy of the complete idiotype, believed to be critical in mounting a full and complete immune response against the cancer, as well as “training” the immune system to maintain continuous response if cancerous cells were to return.

ABOUT IDIS LIMITED

idis is the world leader in the development and implementation of named-patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. idis supports customers in over 100 countries, supplying more than 400 different medicines per month and responding to more than half a million requests on a named-patient basis to medical professionals worldwide.

NEXMED INCORPORATED (NASDAQ: NEXM)
"Up 22.23% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/NEXM.php

NexMed’s pipeline includes its innovative topical onychomycosis treatment, which is licensed to Novartis for global development, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 treatment for female sexual arousal disorder, and an early stage treatment for psoriasis.

NEXM News:

June 19 - TheFortuneFinancial.com Free Market Research on NEXM, SPPI, URBN and ASML

The Following Is an Investment Opinion Being Issued by TheFortuneFinancial.com.

On June 19, TheFortuneFinancial.com asked some of the top analysts worldwide to give their updated feedback regarding the current market activity and position on NexMed Inc. (Nasdaq: NEXM), Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI), Urban Outfitters Inc. (Nasdaq: URBN) and ASML Holding NV (Nasdaq: ASML).

To have free access to these analyst opinions, sign up now to www.thefortunefinancial.com by clicking the link below.

http://www.thefortunefinancial.com/index.php?id=78

All analyst reviews will be posted for free under "today's articles" within 24 hours they are advertised online.

Each interview will vary and may include, but will not be limited to the following:

– An Unbiased View of the Company
– Short–term Target Prices
– Long–term Resistance and Support Levels
– Analyst Opinions
– Sector Review
– Competition Overview